4 hospitals allowed to use molnupiravir to treat COVID-19

This handout photo obtained May 26, 2021, courtesy of Pharmaceutical company Merck shows capsules of the experimental antiviral drug Molnupiravir. Merck said on October 1, 2021, it will seek authorization in the US for molnupiravir for Covid-19, after the pill showed "compelling results" in a clinical trial. The experimental drug, significantly reduced the risk of hospitalization or death when administered to high-risk patients early in the disease, Merck and its partner Ridgeback Biotherapeutics said in a statement.

Handout / Merck & Co, Inc. / AFP

MANILA, Philippines — While molnupiravir is still undergoing clinical trials, the Food and Drug Administration (FDA) said yesterday that four hospitals have been granted compassionate special permit (CSP) to use the drug to treat their COVID-19 patients.

FDA director general Eric Domingo said molnupiravir, an investigational antiviral drug to treat COVID-19, can now be applied for CSP with his agency.

He noted that “multi-countries,” including the Philippines, are doing clinical trials for the drug.

Full Story: https://www.philstar.com/headlines/2021/10/07/2132299/4-hospitals-allowed-use-molnupiravir-treat-covid-19